Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paroxetine hydrochloride
Drug ID BADD_D01680
Description Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others.[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.[A31914] Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.[A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Indications and Usage Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
Marketing Status Prescription; Discontinued
ATC Code N06AB05
DrugBank ID DB00715
KEGG ID D05374
MeSH ID D017374
PubChem ID 62878
TTD Drug ID D06GDY
NDC Product Code 65862-154; 67544-492; 61187-005; 65841-099; 60429-735; 68084-046; 68788-0797; 0904-5678; 16714-182; 60505-4377; 60505-3675; 60505-0101; 60505-0402; 70518-0993; 50090-0849; 65841-097; 60505-4519; 68084-047; 0904-5679; 60505-4517; 65841-601; 43353-845; 69986-011; 50090-0922; 60505-4518; 0904-5676; 68084-044; 68071-4323; 50090-5566; 60505-3670; 60505-4379; 60429-734; 71335-0572; 60505-0097; 60505-1316; 68084-045; 60505-0084; 68788-9074; 70518-1460; 60505-4520; 60429-737; 60505-1318; 65841-098; 65862-156; 60505-4378; 60505-1317; 62175-470; 16714-183; 67544-317; 68071-4283; 43353-994; 0904-5677; 65862-155; 60505-3674; 70518-2118; 60505-0083; 71335-1882; 62175-472; 49999-632; 63629-8527; 65862-157; 71610-348; 50090-1296; 70518-2871; 16714-181; 69986-012; 16714-184; 55154-7999; 60505-3673; 71335-1205; 62175-471; 60505-3669; 60429-736
Synonyms Paroxetine | Aropax | BRL-29060 | BRL 29060 | BRL29060 | FG-7051 | FG 7051 | FG7051 | Paroxetine Acetate | Seroxat | Paroxetine Hydrochloride Anhydrous | Paroxetine Maleate | Paroxetine, cis-(+)-Isomer | Paroxetine, cis-(-)-Isomer | Paroxetine, trans-(+)-Isomer | Paxil | Paroxetine Hydrochloride Hemihydrate | Paroxetine Hydrochloride, Hemihydrate | Paroxetine Hydrochloride
Chemical Information
Molecular Formula C19H21ClFNO3
CAS Registry Number 78246-49-8
SMILES C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Metabolic disorderActivity-regulated cytoskeleton-associated proteinQ9WV31Not AvailableNot Available
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Cholelithiasis09.03.01.002--Not Available
Choreoathetosis17.01.01.003--Not Available
Cogwheel rigidity17.01.05.001; 15.05.04.006--Not Available
Colitis07.08.01.001--
Confusional state17.02.03.005; 19.13.01.001--
Conjunctival oedema06.04.01.001--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Conversion disorder19.24.01.001--Not Available
Coordination abnormal17.02.02.004--Not Available
Cystitis11.01.14.001; 20.03.02.002--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Delirium19.13.02.001--
Delusion19.10.01.001--
Dental caries07.09.01.001--
Dermatitis bullous23.03.01.002--
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.003--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.002--Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug dependence19.07.02.009--Not Available
Dry mouth07.06.01.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages